Home
About
Overview
Sharing Data
ORCID
Help
History (2)
Burkitt Lymphoma International Prognostic Index.
Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma.
See All 2 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Burkitt Lymphoma International Prognostic Index.
Burkitt Lymphoma International Prognostic Index. J Clin Oncol. 2021 04 01; 39(10):1129-1138.
View in:
PubMed
subject areas
Adult
Antineoplastic Combined Chemotherapy Protocols
Australia
Burkitt Lymphoma
Canada
Cohort Studies
Europe
Female
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Multivariate Analysis
Prognosis
Rituximab
United States